Scarica l'app Stockscreener
27.80
1.14%
-0.32
Dopo l'orario di chiusura:
27.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$28.12
Aprire:
$28.145
Volume 24 ore:
34.92M
Relative Volume:
0.95
Capitalizzazione di mercato:
$158.45B
Reddito:
$63.32B
Utile/perdita netta:
$7.52B
Rapporto P/E:
21.31
EPS:
1.3043
Flusso di cassa netto:
$9.48B
1 W Prestazione:
-3.03%
1M Prestazione:
-4.20%
6M Prestazione:
-1.84%
1 anno Prestazione:
+2.66%
Intervallo 1D:
$27.44
$28.16
Intervallo di 1 settimana:
$27.44
$28.95
Portata 52W:
$23.62
$29.21
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.80 | 163.41B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer stock after-hours at EUR 25.04: minus 0.67 percent - AD HOC NEWS
Pfizer Says Eczema Drug Shows Significant Skin Clearance - Benzinga
Form 4 Pfizer For: 1 October By Investing.com - Investing.com Canada
Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims - WTVB
Florida files lawsuit against Pfizer over COVID-19 vaccineReuters - Українські Національні Новини (УНН)
Does Pfizer (PFE) Have A New Growth Driver In Tilrekimig? - Simply Wall Street
Florida sues Pfizer and CEO Albert Bourla over COVID vaccine claims - Investing.com India
Pfizer Scores Promising Win for Experimental Eczema Drug - Yahoo Finance
Pfizer Sued By Florida AG Over its Covid-19 Vaccine Marketing - Bloomberg Law News
Florida AG sues Pfizer over 'misconduct' related to COVID vaccine risks - Seeking Alpha
Pfizer Sued by Florida Attorney General Over COVID-19 Vaccine Marketing - marketscreener.com
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - Yahoo Finance
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - 247wallst.com
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win - Zacks Investment Research
Pfizer Reports Tilrekimig Phase 2 Atopic Dermatitis Results - grafa.com
Pfizer eczema drug succeeds in mid-stage study (PFE:NYSE) - Seeking Alpha
Pfizer presents tilrekimig data while Pfizer stock stays near its prior close - AD HOC NEWS
Pfizer reports positive phase 2 results for atopic dermatitis drug By Investing.com - Investing.com Canada
Pfizer Inc details 61% EASI‑75 response in tilrekimig trial - Mugglehead Investment Magazine
Pfizer’s Phase II Atopic Dermatitis Data Push Tilrekimig Into Pivotal AD, Asthma Trials - insights.citeline.com
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study - Business Wire
Are You Overpaying For Pfizer Stock Versus Its Rivals? - Trefis
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat - Yahoo Finance
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Bayer Advances Patent Suit Over Moderna, Pfizer Covid Vaccines - Bloomberg Law News
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects? - Yahoo Finance
Pfizer and Moderna Lose Bids to Escape Bayer mRNA Patent Lawsuits - Lawyer Monthly
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE) - Seeking Alpha
Bayer's COVID Vax IP Suits Against Moderna, Pfizer Survive - Law360
Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE) - Seeking Alpha
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit - reuters.com
Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says - marketscreener.com
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - Yahoo Finance
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? - Yahoo Finance
Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing? - Yahoo Finance
Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside? - Yahoo Finance
Pfizer (PFE) Balances Global Pricing Opportunity with New Revenue Sharing - Yahoo Finance
Pfizer Inc. - Britannica
How AI Is Helping Match Patients to Clinical Trials Faster - Pfizer
Pfizer Inc Lobbyists, 2013 - OpenSecrets
Pfizer (NYSE:PFE) Back In Focus As Pricing Deal, Migraine Study, And Vaccine Milestone Shape Its Reset - Kalkine Media
Pfizer (PFE) Bets Big on RSV and Cancer Care - TipRanks
Pfizer: Buy Before The Street Catches Up To Its Own Numbers (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) Targets Air Traffic Fees Over Unpaid Vaccines. Can it Turn a Court Win Into Cash? - Insider Monkey
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? - Yahoo Finance
Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study - TipRanks
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
Pfizer stock reports a Q2 earnings beat at USD 28.43 - AD HOC NEWS
Pfizer stock heads into the open after a 0.82 percent gain - AD HOC NEWS
What Could Pfizer (PFE) Unlock From Faster FDA Reviews And Orphan Drug Growth? - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):